Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising data in initial human studies. Ongoing inquiry suggests https://bookmarklethq.com/story21336139/retatrutide-emerging-studies-and-potential-clinical-uses